Last checked at 31 Jan 2022 14:09
31 January 2022
Nuformix plc
("Nuformix" or the "the Company")
Director/PDMR Shareholding
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that it has granted a total of 3,000,000 warrants each to Dr Alastair Riddell, Dr Julian Gilbert and Maddy Kennedy with an exercise price of 1.45p per share.
- Ends -
Enquiries:
Nuformix plc | via Walbrook | ||||
Dr Alastair Riddell, Executive Chairman | |||||
Allenby Capital Limited |
+44 (0) 20 3328 5656 | ||||
Nick Athanas / George Payne (Corporate Finance) | |||||
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking) | |||||
Walbrook PR |
nuformix@walbrookpr.com or +44 (0)20 7933 8780 | ||||
Anna Dunphy / Phillip Marriage | Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082 | ||||
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Dr Alastair Riddell | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| PDMR - Executive Chairman | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Nuformix plc | ||||
b)
| LEI
| 2138003XG3H3I2J3BJ24 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Warrants to acquire ordinary shares at a price of 1.45p per share.
GB00BYW79Y38 | ||||
b)
| Nature of the transaction
| Granting of warrants | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | Single Transaction
| ||||
e)
| Date of the transaction
| 31 January 2022 | ||||
f)
| Place of the transaction
| Off-market transaction | ||||
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Dr Julian Gilbert | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| PDMR - Non-executive Director | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Nuformix plc | ||||
b)
| LEI
| 2138003XG3H3I2J3BJ24 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Warrants to acquire ordinary shares at a price of 1.45p per share.
GB00BYW79Y38 | ||||
b)
| Nature of the transaction
| Issue of warrants | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | Single Transaction
| ||||
e)
| Date of the transaction
| 31 January 2022 | ||||
f)
| Place of the transaction
| Off-market transaction | ||||
1
| Details of the person discharging managerial responsibilities / person closely associated
| |||||
a)
| Name
| Maddy Kennedy | ||||
2
| Reason for the notification
| |||||
a)
| Position/status
| PDMR - Non-executive Director | ||||
b)
| Initial notification /Amendment
| Initial notification | ||||
3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |||||
a)
| Name
| Nuformix plc | ||||
b)
| LEI
| 2138003XG3H3I2J3BJ24 | ||||
4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Warrants to acquire ordinary shares at a price of 1.45p per share.
GB00BYW79Y38 | ||||
b)
| Nature of the transaction
| Issue of Warrants | ||||
c)
| Price(s) and volume(s)
|
| ||||
d)
| Aggregated information | Single Transaction
| ||||
e)
| Date of the transaction
| 31 January 2022 | ||||
f)
| Place of the transaction
| Off-market transaction | ||||